PCSK9 and systemic lupus erythematosus: Regarding specific lipid-targeted therapeutics, statins have shown mixed outcomes in both adult SLE and JSLE trials [50–55], and evidence suggests that both statins and PCSK9 therapies have a low impact on HDL particle concentration and cholesterol content [56], providing evidence that new therapeutic strategies to increase HDL for adequate management of atherosclerosis risk are needed both in SLE and in the general population.